194 related articles for article (PubMed ID: 31975352)
21. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
22. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
[TBL] [Abstract][Full Text] [Related]
23. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
24. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
[TBL] [Abstract][Full Text] [Related]
26. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
[TBL] [Abstract][Full Text] [Related]
27. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
29. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
Motovska Z; Hlinomaz O; Kala P; Hromadka M; Knot J; Varvarovsky I; Dusek J; Jarkovsky J; Miklik R; Rokyta R; Tousek F; Kramarikova P; Svoboda M; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
J Am Coll Cardiol; 2018 Jan; 71(4):371-381. PubMed ID: 29154813
[TBL] [Abstract][Full Text] [Related]
30. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.
Giannitsis E; Wallentin L; James SK; Bertilsson M; Siegbahn A; Storey RF; Husted S; Cannon CP; Armstrong PW; Steg PG; Katus HA;
Eur Heart J Acute Cardiovasc Care; 2017 Sep; 6(6):500-510. PubMed ID: 27044282
[TBL] [Abstract][Full Text] [Related]
31. Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Chin CT; Boden WE; Roe MT; Neely B; Neely ML; Leiva-Pons JL; Corbalán R; Gottlieb S; Dalby AJ; Armstrong PW; Prabhakaran D; Fox KA; White HD; Ohman EM; Winters KJ; Schiele F
Heart; 2016 Aug; 102(15):1221-9. PubMed ID: 27030601
[TBL] [Abstract][Full Text] [Related]
32. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
[TBL] [Abstract][Full Text] [Related]
33. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Olivier CB; Mulder H; Hiatt WR; Jones WS; Fowkes FGR; Rockhold FW; Berger JS; Baumgartner I; Held P; Katona BG; Norgren L; Blomster J; Patel MR; Mahaffey KW
JAMA Cardiol; 2019 Jan; 4(1):7-15. PubMed ID: 30540355
[TBL] [Abstract][Full Text] [Related]
34. Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.
Gue YX; Kanji R; Wellsted DM; Srinivasan M; Wyatt S; Gorog DA
J Thromb Thrombolysis; 2020 Feb; 49(2):192-198. PubMed ID: 31872349
[TBL] [Abstract][Full Text] [Related]
35. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
37. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
Franchi F; James SK; Ghukasyan Lakic T; Budaj AJ; Cornel JH; Katus HA; Keltai M; Kontny F; Lewis BS; Storey RF; Himmelmann A; Wallentin L; Angiolillo DJ;
J Am Heart Assoc; 2019 Mar; 8(6):e011139. PubMed ID: 30857464
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic experience of ticagrelor in Indian patients with acute coronary syndrome: A non-interventional, prospective, and observational study.
Sawhney JPS; Dalal J; Mullasari A; Bansal S; Kahali D
Indian Heart J; 2019; 71(4):344-349. PubMed ID: 31779864
[TBL] [Abstract][Full Text] [Related]
39. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Armstrong PW; Siha H; Fu Y; Westerhout CM; Steg PG; James SK; Storey RF; Horrow J; Katus H; Clemmensen P; Harrington RA; Wallentin L
Circulation; 2012 Jan; 125(3):514-21. PubMed ID: 22179530
[TBL] [Abstract][Full Text] [Related]
40. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
